El Paso, TX, January 7, 2015 — Premier Biomedical, Inc. (OTCBB: BIEI) announced that they developed an Ebola Virus treatment and filed a related Provisional Patent Application in the fourth quarter of 2014.Premier Biomedical also submitted the Ebola treatment to the Food and Drug Administration (FDA) to outline requirements for investigational testing to determine both safety and efficacy of the technology.
The technology involved in the Ebola Virus treatment utilizes Premier Biomedical’slicensed patented method to fight disease-causing molecular compoundsoutside of the body by “Physically removing the pathophysiologic basis of disease™.” As part of the FDA submission, Premier Biomedical provided 3-D CAD models of its proprietaryhardware and is in the process of producing working prototypes.
Premier Biomedical’s President & CEO, William A. Hartman, stated that, “This is the first of a number of filings we plan to make with the FDA in short order. We are pleased with their entire response process,and are anxious to get the FDA regulatory process on a number of biomedical devices and treatmentsbehind us, so that we can get our products tothe market and relieve suffering as soon as possible.”
“We are very excited about our breakthrough and innovative technology regarding Ebola,” said Mitchell S. Felder, M.D., Premier Biomedical’s chair of the scientific advisory board. “Our discussion with the U.S. Food and Drug Administration will further detail the testing requirements to establish safety and efficacy of our proprietary device. We plan to begin that testing process as soon as possible, so that this very promising technology can be marketed to address this desperate global health need.”
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.